TRIM63 (Tripartite Motif Containing 63), also known as MURF-1 (Muscle-Specific RING Finger Protein 1), is a muscle-specific E3 ubiquitin ligase that plays a critical role in protein degradation pathways 1. While primarily studied in the context of skeletal and cardiac muscle biology, TRIM63 has emerging connections to neurodegenerative diseases through pathways involving protein homeostasis, autophagy, and muscle-brain interactions.
[^2]
| Property | Value |
|----------|-------|
| Gene Symbol | TRIM63 |
| Gene Name | Tripartite Motif Containing 63 (MURF-1) |
| Aliases | MURF-1, IRF, RNF28 |
| Chromosomal Location | 1p36.22 |
| NCBI Gene ID | 55177 |
| OMIM | 606471 |
| UniProt | Q9C0B1 |
| Ensembl | ENSG00000146070 |
TRIM63 functions as an E3 ubiquitin ligase, specifically targeting proteins for degradation via the ubiquitin-proteasome system (UPS). Key substrates include:
- Myosin heavy chain (MyHC): Structural protein in muscle fibers 2
- Troponin I: Regulatory protein in muscle contraction
- Titin: Large protein responsible for muscle elasticity
- Nuclear proteins: Involved in gene regulation
TRIM63 is a key mediator of muscle atrophy pathways:
- FoxO transcription factors: Activated during atrophy, upregulate TRIM63 expression 3
- Akt/mTOR signaling: Inhibits TRIM63 when active; loss of Akt signaling promotes expression
- Inflammatory cytokines: TNF-α and IL-6 can induce TRIM63 transcription
- Oxidative stress: Increases TRIM63 levels in muscle tissue
TRIM63 interacts with autophagy pathways:
- LC3 interaction: Can bind to autophagy-related proteins 4
- Selective autophagy: Targets damaged proteins for autophagic degradation
- Mitophagy: May influence mitochondrial quality control in muscle
TRIM63 shows highly restricted expression:
- Skeletal muscle: Highest expression in fast-twitch (type II) fibers
- Cardiac muscle: Moderate expression in heart tissue
- Brain: Very low to undetectable under normal conditions
- Other tissues: Minimal expression
TRIM63 expression is tightly regulated by:
- Transcriptional control: FoxO1, FoxO3, and NF-κB response elements
- Hormonal signaling: Glucocorticoids, thyroid hormone
- Activity-dependent: Disuse and unloading increase expression
- Circadian regulation: Shows diurnal variation in muscle
TRIM63 plays a significant role in age-related muscle loss (sarcopenia):
- Upregulation in aging: TRIM63 expression increases with age in skeletal muscle
- Protein degradation: Enhanced ubiquitin-proteasome activity contributes to muscle fiber loss
- Therapeutic targeting: Inhibition of TRIM63 may preserve muscle mass in elderly 5
Connections between TRIM63 and ALS include:
- Muscle involvement: ALS patients show elevated TRIM63 in muscle biopsies 6
- Denervation atrophy: Motor neuron degeneration leads to muscle TRIM63 upregulation
- Biomarker potential: TRIM63 as a marker of muscle involvement in ALS
- Preclinical studies: Murf1 knockout mice show improved muscle function in ALS models
TRIM63 dysregulation in muscular dystrophies:
- Duchenne Muscular Dystrophy (DMD): Elevated TRIM63 in muscle biopsies
- Limb-Girdle Muscular Dystrophies: Variable TRIM63 expression patterns
- Myotonic Dystrophy: TRIM63 upregulation correlates with disease severity
In cardiac muscle:
- Heart failure: TRIM63 expression increases in failing hearts 7
- Cardiac atrophy: Associated with pathological cardiac remodeling
- Pressure overload: Mechanical stress induces TRIM63 in cardiac tissue
The muscle-brain axis provides connections between peripheral muscle function and neurodegenerative diseases:
- Exercise effects: Physical activity reduces TRIM63 in muscle and may have neuroprotective effects
- Myokines: Muscle-secreted factors influence brain function
- Metabolic health: Muscle metabolism affects systemic inflammation
Chronic inflammation in neurodegeneration affects muscle:
- Cytokine signaling: Peripheral IL-6, TNF-α cross the blood-brain barrier
- Muscle inflammation: Neurodegeneration can cause muscle inflammatory responses
- TRIM63 regulation: Inflammatory cytokines upregulate muscle TRIM63
TRIM63 as a therapeutic target:
- Small molecule inhibitors: Under development for muscle wasting disorders
- Antisense oligonucleotides: ASO-based approaches to reduce TRIM63 expression
- Natural compounds: Some flavonoids and polyphenols inhibit TRIM63 transcription
- Combination therapies: TRIM63 inhibition with exercise and nutrition
- Knockout mice: Murf1-/- mice show resistance to muscle atrophy
- Cell culture: C2C12 myotubes for in vitro studies
- Tissue samples: Human muscle biopsies from patients
- qPCR: mRNA expression analysis
- Western blot: Protein level detection
- Immunohistochemistry: Tissue localization
- Enzyme activity: Ubiquitin ligase activity assays
¶ Interactions and Pathways
TRIM63 interacts with:
- Ubiquitin-conjugating enzymes: UBE2D2, UBE2L3
- Muscle structural proteins: Myosin, troponin, titin
- Transcription factors: FoxO1, FoxO3
- Autophagy proteins: LC3, p62
- Akt/mTOR: Negative regulation when active
- FoxO transcription factors: Direct transcriptional activation
- NF-κB signaling: Inflammatory cytokine-mediated induction
- MAPK pathways: Stress-activated signaling
TRIM63 as a biomarker:
- Blood levels: Detectable in serum; correlates with muscle mass
- Disease progression: Levels track with disease severity in some conditions
- Therapeutic monitoring: May predict response to atrophy treatments
Current approaches:
- Pharmacological inhibitors: Preclinical development
- Gene therapy: AAV-mediated knockdown approaches
- Repurposing: Existing drugs that modulate TRIM63